First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and ...

Summary of BioAge Labs FY Conference Call Company Overview - **Company**: BioAge Labs (NasdaqGS:BIOA) - **Focus**: Development of therapeutics targeting metabolic aging and obesity Key Points Platform and Data - BioAge Labs has developed a unique platform with approximately **50 million molecular data points** collected over decades, making it one of the largest human aging data sets globally [5][6] - The platform focuses on identifying targets for metabolic aging, particularly in the context of obesity and related comorbidities [5][6] - Recently expanded its discovery capabilities by incorporating data from the **HUNT Biobank** in Norway, which includes over **30 years of health records** and a significant portion of individuals developing cardiometabolic diseases [12] Therapeutic Focus - The company is concentrating on the next generation of obesity therapies that address not only weight loss but also muscle loss and inflammation [6] - BioAge Labs is advancing its lead program, **BGE-102**, a brain-penetrant NLRP3 inhibitor, which has shown promising preclinical results in weight loss comparable to semaglutide [25][26] - The mechanism of BGE-102 targets neuroinflammation, which is linked to appetite dysregulation and obesity [25] Collaborations - BioAge Labs has established collaborations with major pharmaceutical companies, including **Novartis** and **Eli Lilly**. The Novartis partnership focuses on novel target discovery related to aging biology and exercise [18][21] - The collaboration with Eli Lilly involves developing molecules based on BioAge's human data, allowing for expanded capabilities in drug development [21] Clinical Development - BGE-102 has initiated a **Phase 1 study** with results expected by the end of the year, focusing on pharmacodynamics (PD) and safety [30][35] - The company plans to advance into a monotherapy obesity trial following the Phase 1 results, with a robust design aimed at weight loss [47] Financial Position - As of June, BioAge Labs reported over **$310 million** in cash, sufficient to fund operations for over three years, covering ongoing studies and development milestones [71] Future Catalysts - Upcoming catalysts include the **SAD data** by the end of the year, **MAD data** in the first half of 2026, and IND filings for APJ agonist programs by the end of 2026 [73] - External catalysts include data readouts from competitors, which may provide insights into the market landscape [74] Market Position and Strategy - BioAge Labs aims to leverage its unique platform to explore novel targets, differentiating itself from competitors who focus on validated targets [75] - The company is also exploring the integration of **artificial intelligence** in its operations, particularly in target discovery and molecule identification [77][81] Conclusion - BioAge Labs is positioned to capitalize on its extensive data platform and strategic collaborations to develop innovative therapies for metabolic aging and obesity, with a strong financial foundation to support its clinical and operational goals.

BioAge Labs (BIOA) Conference Summary Company Overview - BioAge Labs focuses on understanding mechanisms of aging and metabolic aging using longitudinal human data from biobanks [4][5] - The company has collaborations with Novartis and Lilly for target discovery and drug development [5] Key Programs and Developments NLRP3 Program (BGE 102) - BGE 102 is an oral, CNS-penetrant molecule targeting obesity, with potential best-in-class properties [6][7] - The molecule shows high potency in inhibiting IL-1 beta and has a novel binding site on NLRP3 [7][10] - Preclinical data indicates significant weight loss effects comparable to semaglutide, both as a monotherapy and in combination with incretin therapies [18][19][31] - The mechanism of action involves appetite suppression driven by neuroinflammation [15][16] - A Phase 1 study has commenced, with expected data on safety and IL-1 beta inhibition by the end of the year [23][25] APJ Program - The APJ program includes alternative oral small molecules and a nanobody, aiming to amplify weight loss and preserve muscle [51][52] - The goal is to file an IND for the oral small molecules next year, with potential for a monthly dosing regimen for the nanobody [52][66] - APJ has shown preclinical and clinical potential in preserving muscle, particularly in older populations [55][60] Market Position and Competitive Landscape - The oral obesity treatment market is considered wide open, with significant room for novel mechanisms [35] - BioAge aims to differentiate itself by combining mechanisms that enhance weight loss while maintaining tolerability [39] - The company is closely monitoring competitors' readouts, particularly from Ventex and Nodthera, to inform its strategy [34][41] Financial Outlook - As of June, BioAge had approximately $313 million in cash, providing a runway of over three years [89] - The company is focused on capitalizing on partnerships and collaborations to lower costs and enhance funding opportunities [90][91] Strategic Vision - BioAge envisions advancing a portfolio of differentiated mechanisms into clinical trials, targeting obesity and its comorbidities [80] - The company is exploring additional partnerships and collaborations to expand its pipeline and capabilities [78][79] Conclusion - BioAge Labs is positioned to be a leader in the obesity treatment space with its innovative approaches and strong pipeline, focusing on both NLRP3 and APJ mechanisms [100][101]